RedHill Biopharma (RDHL) Gross Margin (2014 - 2023)

RedHill Biopharma (RDHL) has 9 years of Gross Margin data on file, last reported at 55.12% in Q2 2023.

• On a quarterly basis, Gross Margin rose 415.0% year-over-year to 55.12% in Q2 2023; TTM through Jun 2023 was 42.74%, a 111.0% increase from a year earlier, with the FY2025 full-year figure at 1927.62%, up 186732.0% from the prior year.
• Gross Margin for Q2 2023 stood at 55.12%, roughly flat from 55.21% in the prior quarter.
• Over the last five years, Gross Margin for RDHL reached as high as 75.99% in Q1 2019 and fell as low as 62.41% in Q1 2020.
• Historically, Gross Margin has averaged 43.77% across 5 years, with a median of 50.7% in 2020.
• Across the five-year window, Gross Margin plunged 13840 bps in 2020 and jumped 11257 bps in 2021, its largest moves.
• Year by year, Gross Margin stood at 50.44% in 2019, then declined by 0 bps to 50.37% in 2020, then plunged by 75 bps to 12.4% in 2021, then soared by 165 bps to 32.82% in 2022, then soared by 68 bps to 55.12% in 2023.
• Per Business Quant data, the three most recent Gross Margin figures were 55.12% in Q2 2023, 55.21% in Q1 2023, and 32.82% in Q4 2022.